Price
$2.18
Decreased by -4.80%
Dollar volume (20D)
446.83 K
ADR%
6.51
Shares float
4.58 M
Shares short
492.41 K [10.75%]
Shares outstanding
8.98 M
Market cap
19.57 M
Beta
0.05
Price/earnings
N/A
20D range
1.90 2.45
50D range
1.07 2.70
200D range
0.95 2.85

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.

The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old.

It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.

The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.

Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 13, 25 0.21
Increased by +140.38%
-0.64
Increased by +132.81%
Feb 5, 25 0.13
Increased by +425.00%
-0.28
Increased by +146.43%
Nov 12, 24 -0.15
Increased by +89.86%
-0.34
Increased by +55.88%
Sep 25, 24 -0.82
Decreased by -38.98%
-0.45
Decreased by -82.22%
May 15, 24 -0.52
Increased by +73.06%
-0.64
Increased by +18.75%
Feb 14, 24 -0.04
Increased by +96.95%
-0.25
Increased by +84.00%
Nov 14, 23 -1.48
Decreased by -23.33%
-0.04
Decreased by -3.60 K%
Sep 27, 23 -0.59
Increased by +93.98%
-0.95
Increased by +37.89%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 18.45 M
Increased by +2.55%
3.99 M
Increased by +238.20%
Increased by +21.65%
Increased by +234.76%
Dec 31, 24 16.22 M
Decreased by -29.27%
788.00 K
Increased by +458.18%
Increased by +4.86%
Increased by +606.41%
Sep 30, 24 16.57 M
Decreased by -25.00%
1.47 M
Increased by +118.15%
Increased by +8.89%
Increased by +124.20%
Jun 30, 24 17.98 M
Decreased by -41.51%
-4.62 M
Decreased by -87.91%
Decreased by -25.68%
Decreased by -221.26%
Mar 31, 24 17.99 M
Decreased by -20.85%
-2.89 M
Increased by +59.86%
Decreased by -16.06%
Increased by +49.29%
Dec 31, 23 22.93 M
Decreased by -12.73%
-220.00 K
Increased by +96.71%
Decreased by -0.96%
Increased by +96.23%
Sep 30, 23 22.10 M
Decreased by -20.09%
-8.12 M
Decreased by -91.65%
Decreased by -36.74%
Decreased by -139.83%
Jun 30, 23 30.73 M
Increased by +11.96%
-2.46 M
Increased by +84.73%
Decreased by -7.99%
Increased by +86.36%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY